Neutron Delay Overshadows Sold-Out Backlog; Stock Slips as Execution Risk Persists
Read source articleWhat happened
Rocket Lab's Q3 results revealed Neutron debut pushed to 2027 after composite tank dome defect, despite strong demand with eight missions signed worth $515M and backlog through 2030s. Stock fell after earnings because investors focused on schedule slip rather than long-dated order book. Only 33% of $3.573B backlog is scheduled within 12 months, and Neutron revenue remains deferred. Meanwhile core business improved with Q3 revenue $267.8M, positive operating cash flow $7.2M, and contract liabilities up to $423.6M. But overall nine-month operating loss $192.7M and elevated capex keep execution risk front and center.
Implication
Demand is validated but conversion timing remains uncertain, so the stock's premium to tangible milestones is still too high. The Neutron delay pushes revenue and NSSL optionality further out while R&D and capex stay elevated, compressing near-term valuation support. Q4 guidance of $270-$290M revenue and 34%-36% gross margin will test whether Space Systems can bridge the gap. If contract liabilities fail to grow or Iridium close slips beyond mid-2027, downside to low-$40s bear case becomes plausible. Conversely, disclosure of pad delivery and integrated testing by mid-2027 would support a move toward $78 bull case; until then, patience is warranted.
Thesis delta
The thesis does not change materially after the article, but the earnings reaction reinforces that schedule credibility, not backlog size, is the key driver. The prior WAIT stance stays valid: current price $58.9 already reflects substantial medium-lift value that still needs observable execution proof.
Confidence
Medium